bioMérieux share: the stock settles above its 79.70 € resistance level
The in vitro diagnostics manufacturer is standing out sharply from a slightly rising Paris stock exchange. The stock is extending a rebound initiated since late September and ranks among the top performers of its index.
A resistance overcome during trading and a price at the doorstep of its 200-day moving average
The bioMérieux stock gains 4.61% to 81.75 €, placing it among the strongest gains of the SBF 120, while the index advances 0.66%. It has overcome its resistance at 79.70 € during trading and is holding above it, following a surge of more than 12% in one week at the end of September. The price is now 9.8% above its 20-day moving average (74.46 €), but still 1.55% below the 200-day moving average at 83.04 €. Over one month, the stock gains 10.1%, while its decline over one year remains 29.9%.
A GO-28 plan confirmed and a commercial launch in the background
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
During the first half 2026 results published on August 4, the group confirmed its annual outlook: organic revenue growth between 3% and 5%, and CEBIT up 0% to 10%. The four growth drivers of the GO-28 plan had advanced 6% organically at that time, but the 17% decline in BIOFIRE® respiratory panels and an unfavorable currency effect of 35 M€ had weighed on the period. The group launched at the end of September Spinchip, a troponin test in ten minutes for emergency departments. The 200-day moving average at 83.04 € is the next technical benchmark for the stock.
SectorDiagnostic et services de laboratoire›Diagnostic / labos d'analyse
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 1 965 millions d'euros
Quarterly revenue: 1 965 millions d'euros
Revenue growth: -3,9 %
EBITDA: 440,3 millions d'euros
EBITDA margin: 22,4 %
Net income: 226,1 millions d'euros
Free cash flow: 299 millions d'euros
-235,9 millions d'euros
Guidance from the release
confirme ses perspectives pour 2026 : croissance organique du chiffre d'affaires comprise entre +3% et +5%, CEBIT croissance comprise entre 0% et +10%
Risks mentioned
Épidémiologie respiratoire plus faible : recul organique de 17 % des panels respiratoires BIOFIRE®
Effet de change défavorable de 35 M€ sur le ROCC du premier semestre 2026
Environnement géopolitique et macroéconomique dégradé depuis 2024
Opportunities identified
Croissance organique de 6 % des quatre moteurs de croissance du plan GO•28
Dépôt auprès de la FDA du panel SPOTFIRE® Vaginitis
Obtention du marquage CE du premier test SPINCHIP®
Outlook / guidance
Expected revenue: 4 233 millions d'euros
Management commentary: « organic sales growth expected between +3% and +5% »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
